Heat shock protein 27 mediates repression of androgen receptor function by protein kinase D1 in prostate cancer cells

Oncogene

Volumn 28, Issue 49, 2009, Pages 4386-4396

  Hassan, S ^a   Biswas, M H U ^a   Zhang, C ^a   Du, C ^a   Balaji, K C ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

AR; Hsp27; P38; PKD1; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; HEAT SHOCK PROTEIN 27; PROTEIN KINASE D; PROTEIN KINASE D1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION;

BOMBESIN; BRYOSTATINS; DOWN-REGULATION; ENZYME ACTIVATION; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MALE; MULTIPROTEIN COMPLEXES; NEUROTENSIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN KINASE C; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED;

EID: 72049107813     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.291     Document Type: Article

References (46)

1. Belka C, Ahlers A, Sott C, Gaestel M, Herrmann F, Brach MA. (1995). Interleukin (IL)-6 signaling leads to phosphorylation of the small heat shock protein (Hsp)27 through activation of the MAP kinase and MAPKAP kinase 2 pathway in monocytes and monocytic leukemia cells. Leukemia 9: 288-294.
2. Carraway R, Leeman SE. (1976). Characterization of radioimmu-noassayable neurotensin in the rat. Its differential distribution in the central nervous system, small intestine, and stomach. J Biol Chem 251: 7045-7052.
3. Carraway RE, Hassan S. (2007). Neurotensin receptor binding and neurotensin-induced growth signaling in prostate cancer PC3 cells are sensitive to metabolic stress. Regul Pept 141: 140-153.
4. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M et al. (2000). Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60: 7099-7105.
5. Doppler H, Storz P, Li J, Comb MJ, Toker A. (2005). A phosphorylation state-specific antibody recognizes Hsp27, a novel substrate of protein kinase D. J Biol Chem 280: 15013-15019.
6. Du C, Ge B, Liu Z, Fu K, Chan WC, McKeithan TW. (2006). PCR-based generation of shRNA libraries from cDNAs. BMC Biotechnol 6: 28.
7. Du C, Jaggi M, Zhang C, Balaji KC. (2009). Protein kinase D1-mediated phosphorylation and subcellular localization of beta-catenin. Cancer Res 69: 1117-1124.
8. Dudich IV, Zav0yalov VP, Pfeil W, Gaestel M, Zav0yalova GA, Denesyuk AI et al. (1995). Dimer structure as a minimum cooperative subunit of small heat-shock proteins. Biochim Biophys Acta 1253: 163-168.
9. Edwards J, Bartlett JM. (2005). The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int 95: 1327-1335. (Pubitemid 40799455)
10. Evans IM, Britton G, Zachary IC. (2008). Vascular endothelial growth factor induces heat shock protein (HSP) 27 serine 82 phosphoryla-tion and endothelial tubulogenesis via protein kinase D and independent of p38 kinase. Cell Signal 20: 1375-1384.
11. Fanelli MA, Montt-Guevara M, Diblasi AM, Gago FE, Tello O, Cuello-Carrion FD et al. (2008). P-cadherin and beta-catenin are useful prognostic markers in breast cancer patients; beta-catenin interacts with heat shock protein Hsp27. Cell Stress Chaperones 13: 207-220.
12. Geum D, Son GH, Kim K. (2002). Phosphorylation-dependent cellular localization and thermoprotective role of heat shock protein 25 in hippocampal progenitor cells. J Biol Chem 277: 19913-19921.
13. Gomase VS, Tagore S. (2008). Kinomics. Curr Drug Metab 9: 255-258.
14. Haslbeck M, Buchner J. (2002). Chaperone function of sHsps. Prog Mol Subcell Biol 28: 37-59.
15. Jaggi M, Chauhan SC, Du C, Balaji KC. (2008). Bryostatin 1 modulates beta-catenin subcellular localization and transcription activity through protein kinase D1 activation. Mol Cancer Ther 7: 2703-2712.
16. Jaggi M, Du C, Zhang W, Balaji KC. (2007). Protein kinase D1: a protein of emerging translational interest. Front Biosci 12: 3757-3767.
17. Jaggi M, Rao PS, Smith DJ, Hemstreet GP, Balaji KC. (2003). Protein kinase C mu is down-regulated in androgen-independent prostate cancer. Biochem Biophys Res Commun 307: 254-260. (Pubitemid 36818862)
18. Jaggi M, Rao PS, Smith DJ, Wheelock MJ, Johnson KR, Hemstreet GP et al. (2005). E-cadherin phosphorylation by protein kinase D1/ protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer. Cancer Res 65: 483-492.
19. Ku GY, Ilson DH, Schwartz LH, Capanu M, O0Reilly E, Shah MA et al. (2008). Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 62: 875-880.
20. Lee LF, Guan J, Qiu Y, Kung HJ. (2001). Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 21: 8385-8397.
21. Li J, Chen LA, Townsend Jr CM, Evers BM. (2008). PKD1, PKD2, and their substrate Kidins220 regulate neurotensin secretion in the BON human endocrine cell line. J Biol Chem 283: 2614-2621.
22. Maizels ET, Peters CA, Kline M, Cutler Jr RE, Shanmugam M, Hunzicker-Dunn M. (1998). Heat-shock protein-25/27 phosphor-ylation by the delta isoform of protein kinase C. Biochem J 332 (Pt 3): 703-712.
23. Mak P, Jaggi M, Syed V, Chauhan SC, Hassan S, Biswas H et al. (2008). Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells. Biochem Biophys Res Commun 373: 618-623.
24. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. (2002). The protein kinase complement of the human genome. Science 298: 1912-1934.
25. Martinez V, Tache Y. (2000). Bombesin and the brain-gut axis. Peptides 21: 1617-1625.
26. Moody TW, Chan D, Fahrenkrug J, Jensen RT. (2003). Neuropep-tides as autocrine growth factors in cancer cells. Curr Pharm Des 9: 495-509.
27. Mosca A, Berruti A, Russo L, Torta M, Dogliotti L. (2005). The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest 28: 141-145.
28. Neckers L. (2003). Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr Med Chem 10: 733-739.
29. Parcellier A, Schmitt E, Gurbuxani S, Seigneurin-Berny D, Pance A, Chantome A et al. (2003). HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol Cell Biol 23: 5790-5802.
30. Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ et al. (2006). Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin0s) lymphoma. Clin Cancer Res 12: 5809-5816.
31. Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C et al. (2005). Increased Hsp27 after androgen ablation facilitates andro-gen- independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 65: 11083-11093.
32. Rocchi P, Jugpal P, So A, Sinneman S, Ettinger S, Fazli L et al. (2006). Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int 98: 1082-1089.
33. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L et al. (2004). Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64: 6595-6602.
34. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D et al. (1994). A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78: 1027-1037.
35. Rozengurt E, Rey O, Waldron RT. (2005). Protein kinase D signaling. J Biol Chem 280: 13205-13208.
36. Rybin VO, Guo J, Steinberg SF. (2009). Protein kinase D1 autopho-sphorylation via distinct mechanisms at Ser744/Ser748 and Ser916. J Biol Chem 284: 2332-2343.
37. Simental JA, Sar M, Lane MV, French FS, Wilson EM. (1991). Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 266: 510-518.
38. So A, Hadaschik B, Sowery R, Gleave M. (2007). The role of stress proteins in prostate cancer. Curr Genomics 8: 252-261. (Pubitemid 47240702)
39. Stokoe D, Engel K, Campbell DG, Cohen P, Gaestel M. (1992). Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins. FEBS Lett 313: 307-313.
40. Syed V, Mak P, Du C, Balaji KC. (2008). Beta-catenin mediates alteration in cell proliferation, motility and invasion of prostate cancer cells by differential expression of E-cadherin and protein kinase D1. J Cell Biochem 104: 82-95.
41. Valverde AM, Sinnett-Smith J, Van Lint J, Rozengurt E. (1994). Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain. Proc Natl Acad Sci USA 91: 8572-8576.
42. Wang G, Wang J, Sadar MD. (2008). Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 68: 9918-9927.
43. Wang QJ. (2006). PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci 27: 317-323.
44. Widmann C, Gibson S, Jarpe MB, Johnson GL. (1999). Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79: 143-180.
45. Yuan J, Rozengurt E. (2008). PKD, PKD2, and p38 MAPK mediate Hsp27 serine-82 phosphorylation induced by neurotensin in pancreatic cancer PANC-1 cells. J Cell Biochem 103: 648-662.
46. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P et al. (2007). Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 67: 10455-10465.